IV 
119TH CONGRESS 
1ST SESSION 
H. RES. 484 
Expressing support for the recognition of ‘‘Hidradenitis Suppurativa 
Awareness Week’’. 
IN THE HOUSE OF REPRESENTATIVES 
JUNE 6, 2025 
Mrs. DINGELL submitted the following resolution; which was referred to the 
Committee on Energy and Commerce 
RESOLUTION 
Expressing support for the recognition of ‘‘Hidradenitis 
Suppurativa Awareness Week’’. 
Whereas Hidradenitis Suppurativa (in this resolution referred 
to as ‘‘HS’’) is a chronic, inflammatory skin disease that 
affects approximately 3,300,000 people in the United 
States; 
Whereas HS causes painful, boil-like nodules and abscesses 
anywhere on the body, and can progress to form tunnels 
under the skin and cause extensive scarring; 
Whereas individuals with HS frequently suffer from 5 pri-
mary domains of physical and emotional suffering, pain, 
drainage, odor, itching, and profound psychological dis-
tress; 
VerDate Sep 11 2014 
22:05 Jun 06, 2025
Jkt 059200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6300
E:\BILLS\HR484.IH
HR484
kjohnson on DSK7ZCZBW3PROD with $$_JOB
•HRES 484 IH 
Whereas HS is associated with one of the highest completed 
suicide rates among dermatological diseases, second only 
to melanoma; 
Whereas 75 percent of individuals with HS are misdiagnosed 
or not diagnosed until after age 25, missing critical win-
dows for early intervention and care; 
Whereas delayed diagnosis contributes to worsening disease 
progression, higher healthcare costs, avoidable emergency 
room visits, and unnecessary procedures; 
Whereas individuals are often diagnosed with HS in the 
prime of their lives, affecting their ability to work, main-
tain relationships, and participate fully in society; 
Whereas, as of June 1, 2025, there are only 3 biologic thera-
pies approved by the Food and Drug Administration for 
the treatment of HS; 
Whereas additional research is urgently needed to develop 
new treatments, understand the pathogenesis of the dis-
ease, identify biomarkers of HS, and improve outcomes 
for HS patients; 
Whereas Federal policy can play a critical role in improving 
access to biologic therapies, wound care, and comprehen-
sive care for HS patients; and 
Whereas designating the first week of June as ‘‘Hidradenitis 
Suppurativa Awareness Week’’ would increase public 
awareness, foster understanding, and catalyze progress in 
diagnosing, treating, and ultimately curing HS: Now, 
therefore, be it 
Resolved, That the House of Representatives— 
(1) supports the recognition of ‘‘Hidradenitis 
Suppurativa Awareness Week’’; and 
VerDate Sep 11 2014 
22:05 Jun 06, 2025
Jkt 059200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\HR484.IH
HR484
kjohnson on DSK7ZCZBW3PROD with $$_JOB
•HRES 484 IH 
(2) recognizes the importance of— 
(A) increasing awareness and education 
about HS among the public and health profes-
sionals; 
(B) promoting timely and accurate diag-
nosis of HS through improved screening and 
culturally competent care; 
(C) supporting biomedical research to bet-
ter understand HS pathogenesis, treatment effi-
cacy, and long-term outcomes; 
(D) accelerating the development of effec-
tive treatments and expanding access to exist-
ing therapies for HS; and 
(E) advancing policies that address dis-
parities in access to care for patients with HS 
and improve the quality of life for individuals 
living with HS and the caregivers of such indi-
viduals. 
Æ 
VerDate Sep 11 2014 
22:05 Jun 06, 2025
Jkt 059200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6301
E:\BILLS\HR484.IH
HR484
kjohnson on DSK7ZCZBW3PROD with $$_JOB